Designing drugs with a specific multi-target profile is a promising approach against multifactorial illnesses as Alzheimer's disease. In this work, new indazole ethers that possess dual activity as both cannabinoid agonists CB2 and inhibitors of BuChE have been designed by computational methods. On the basis of this knowledge, the synthesis, pharmacological evaluation and docking studies of a new class of indazoles has been performed. Pharmacological evaluation includes radioligand binding assays with [ 3 H]-CP55940 for CB1R and CB2R and functional activity for cannabinoid receptors on isolated tissue. Additionally, in vitro inhibitory assays of AChE/BuChE and the corresponding competition studies have been carried out. The results of pharmacological tests have revealed that three of these derivatives behave as CB2 cannabinoid agonists and simultaneously show BuChE inhibition. In particular, compounds 3 and 24 have emerged as promising candidates as novel cannabinoids that inhibit BuChE by a non-competitive or mixed mechanism, respectively. On the other hand, both molecules show antioxidant properties.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is currently the leading cause of dementia in the elderly. Despite of the devastating effects of this disease, therapeutic options for treating AD remain limited. This disease is characterized by the formation of cortical amyloid plaques and neurofibrillary tangles in the brain. A biological function affected in AD is the cholinergic neurotransmission, which seems to be closely related to pathological formation of beta-amyloid. This hypothesis asserts that most of the cognitive impairments suffered by AD patients are the consequence of a deficit in acetylcholine (ACh). In this sense, cholinergic drugs like acetylcholinesterase (AChE) inhibitors, including donepezil, rivastigmine, and galantamine, are currently the most prescribed pharmaceuticals for AD [1e4] .
Moreover, Alzheimer's disease is characterized by a significant reduction in AChE activity and an increase in butyrylcholinesterase (BuChE) activity (about 120%). This increase of BuChE activity, especially found in the hippocampus, has been suggested to be related to the loss of episodic memory [5] . Likewise, it has been reported that BuChE might facilitate the transformation of an initial benign form of senile plaque to a malignant form associated with AD [6] . Therefore, the BuChE plays an important role in AD patients, what turns it into an interesting target for the research in the field [5e8].
AChE is characterized by having two sites: a peripheral anionic site (PAS) located at the mouth of the active site gorge, which is regarded as the recognition binding site; and the anionic subsite of the active site (CAS), where acetylcholine (ACh)-fixation is occurring before being hydrolyzed in the active site. The interaction with PAS is assumed to be determinant in both the association of AChE with b-amyloid and the formation of amyloid [9e11] . BuChE, also possessing PAS [12, 13] and CAS, is present in the neuritic plaques together with AChE. By other hand, BuChE-selective inhibitors have been reported to reduce b-amyloid (AB) and b-amyloid precursor (APP) secretion in vitro and in vivo [14, 15] New pharmacological alternatives are focused on the development of new drugs capable of acting at different targets [16] (i.e., multitarget drugs) as compounds with anticholinesterase and NMDA receptor antagonistic activity [17] ; dual inhibitors of histamine H3 receptors and AChE [18] ; dual inhibitors of AChE and BACE1 [19] ; dual acting hybrids BACE1 inhibitor and metal chelator [20] ; dual acting hybrids gamma-secretase modulators with PPARg activity [21] or acetylcholinesterase inhibitors and CB1R antagonist [22] . In this context, cannabinoid compounds are very attractive candidates fit to fit into this paradigm since they could act on different pharmacological targets within the so-called endocannabinoid signalling system, but also on other targets not related to this system. It has been reported that the cannabinoid system is dramatically altered in brains of AD patients [23] . Concerning CB1 receptor, the alteration of this receptor is not so clear. In fact, there is some controversy regarding this issue [24] . Some studies suggest that CB1 receptors are intact in AD and may play a role in preserving the cognitive function [25, 26] , while other studies postulate that the expression and distribution of CB1 are clearly different in AD [27e29] . In any case, it is important to remark the fact that CB1 receptor is located preferentially in damaged neurons in cortical and subcortical areas, which is in accordance to the expected decrease in the levels of this receptor type due to the progressive neuronal loss. Regarding CB2 receptors, different studies show that they are abundantly expressed in neuritic plaque-associated astrocytes and selectively expressed in reactive microglia [30e32] in brains of AD patients, in contrast to their absence or poor expression in these glial cells under healthy conditions. Three potential interventions have been identified using CB2R as target [24] . First, stimulation of CB2 receptors suppresses microglial activation [33, 34] second, a CB2 receptor agonist such as JWH-015 is capable of inducing the removal of native beta-amyloid [25, 31, 35] and third, CB2 receptor agonists suppress the neuroinflammatory process [36] . Taken together, these results suggest that CB1 receptor agonists may interrupt the mechanism of excitotoxicity and CB2 receptor agonists may suppress neuroinflammation and lead to plaque removal.
On the other hand, our group has demonstrated that some cannabinoid agonists such as the aminoalkylindoles (AAI), JWH-015 or WIN 55,212-2 ( Fig. 1) inhibit the AChE in vitro [37] .
Thus, continuing with our effort to develop an efficient strategy to fight against AD and taking advantage of the demonstrated potential of the cannabinoids that are active at both the cholinergic transmission and at the endocannabinoid system, our research group first disclosed a new family of indazole ethers with cholinergic properties and cannabinoid effects showing multitarget drug profile, which opened a novel and interesting therapeutic strategy for AD [38] . Subsequently, a similar approach was published by Rizzo et al. [39] . Herein, we describe the synthesis and biological evaluation of a new family of compounds based on the indazole ether scaffold.
Result and discussion
One possible way to find a hit consists of performing systematic modifications of the structure by variation of functional groups at particular sites. In a first approach, three different positions of the indazole system were considered for modulating the biological activity and were subject to modification. Toward this goal, we proposed a procedure that encompassed docking studies of CB2 receptor model [40] and BuChE (pdb code: 1P0I), synthesis and pharmacological evaluation of the effects of structure variations of the indazole system.
Rational design
Taking into account all above concepts and applying the bioisosterism criterion, we proposed to replace the indole ring by an indazole core, and also introduce an aromatic ether that is well suited for interacting in the binding site of CB2 receptor in a similar way to AAI. Based on the structural superposition of an AAI as JWH-015 with indazole ethers, we designed a virtual library of different indazole derivatives to make a preliminary docking study. For this theoretical study, aimed at evaluating the binding capacity of this new backbone to the receptor, our theoretical model of CB2R* was employed. The virtual library was designed taking account three criteria: i) groups in position 1 and 3 that allow interactions with CB2 receptor, as previously noted in AAI structures; ii) structural variability and iii) synthetic accessibility.
Thus, this initial virtual library was assembled considering as structural variations a hydrogen, or nitro at position 5; benzyl, diisopropylaminoethyl or piperidinoethyl groups at position 1; and benzyl, methoxybenzyl or naphthylmethoxy at position 3 ( Fig. 2) . Preliminary modelling studies led us to find that several of the virtual compounds showed a favourable energy of interaction compared to the AAI compounds and a similar orientation of the indazole skeleton and the indole ring of AAI. On the basis of these modelling results, new substituents were included.
Thus, pentyl, cyclohexylmethyl, benzyl, 4-methoxybenzyl, diisopropylaminoethyl, pyrrolidinyl ethyl, morpholinoethyl or piperidinoethyl were considered as substituents at the 1-position of the indazole core. O-Substituted groups as cyclohexylmethyl, benzyl, 4-methoxybenzyl, 1-naphthylmethyl or 2-naphthylmethyl were selected as substituents at position 3 while hydrogen, bromo, nitro or amino were chosen as substituents at position 5 of the indazole ring (Fig. 2) .
A docking study was performed using our CB2R model (see details in Computational section), as target against the virtual library. The results of the modelling studies indicated that most of the virtual compounds show favourable energy of interaction and similar orientation of the indazole moiety compared to the indole ring in related AAI, being stabilized by means of an aromatic interaction with Phe197. In addition, the groups in R 2 and R 3 are able to interact with key residues as Leu201 and Tyr190 in TM5 respectively. These initial studies showed that, in general, the N1-substituted derivatives have additional interactions with Met115 and Ser161.
Chemistry
Based on docking results we performed the synthesis of a representative set of compounds (1e25) as potential candidates as cannabinoid ligands and ChEs inhibitors ( Table 1) . As it has been commented in the Introduction, this new family of 1-substituted indazole ethers (1e25) has been claimed by us in a PCT patent [38] . The synthetic methodology for accessing the target compounds 1e25 was based on the introduction of the different groups at N-1 position or at the hydroxyl group of the indazole core through well-established N-alkylation or O-alkylation procedures. Three possible strategies or routes were considered depending on the nature of the desired substituents. The overall synthetic methodology showing the three possible routes is presented in Scheme 1.
The direct base-promoted reaction of the starting indazole core with alkyl halides under refluxing ketone solvent (route A) was found to be only useful to obtain disubstituted derivatives with identical groups at both N-and O-positions. For derivatives having different groups at N-1 and OH at C3, routes B and C were applied. The synthetic route B consists of a two-step sequence involving initial alkylation with the a benzylic halide at the more nucleophilic N-1 position of the indazole ethers, and then introduction of the substituent at position 3-OH using different arylmethyl halides. The main limitation of this route is that it proved to be effective only for selective N-alkylation with highly reactive methyl or arylmethyl halides.
A more structurally versatile and general synthetic route for the formation of substituted indazoles, the route C, comprises three steps involving protection of position N-1 as a carbamate, Oalkylation to furnish the corresponding ether and subsequent deprotection and introduction of the second substituent at the N-1 position.
Following the route A, a wide variety of N-1 substituted indazole ethers were prepared by reaction of indazolol 26 or 5-nitroindazolol 27 [41] with the corresponding halides in acetone or butanone and caesium or potassium carbonate as base (Table 1 , Scheme 2). Thus, the synthesis of indazole ethers 1, 2, 4, 8 were carried out starting from 26 and cyclohexylmethyl, benzyl or 4-methoxybenzyl bromides or 1-naphthylmethyl chloride, respectively. Similarly, the 5-nitroindazole ethers 10, 12 [42] 16, 21 were Table 1 Binding affinities (K i , mM) for CB1 and CB2 receptors of indazole derivatives 1e25. prepared by reaction of 5-nitro-3-indazolole 27 with the corresponding halides of pentyl, benzyl and 1 or 2-naphthylmethyl, respectively. The first attempts to synthesize 1,3-disubstituted indazoles with different groups at N-1 position and ether function were carried out following the synthetic route B starting from 5-nitroindazolole 27. Thus, the reaction of 27 with benzyl bromide in an aqueous solution of sodium hydroxide afforded the corresponding 1-benzyl-3-indazolol 28 [43] . Then, subsequent O-alkylation of 28 with cyclohexylmethyl or 2-naphthylmethyl bromide afforded the indazole ethers 11 and 20.
As mentioned before, the route C was found to be a more versatile and suitable procedure for the sequential two-fold alkylation (at N-and O-centres) with different groups. This strategy resulted especially useful for the preparation of indazole ethers bearing aminoethyl groups at N-1 position. Thus, standard N1-protection of indazoles 26 and 27 with ethyl chloroformiate furnished the corresponding 1-ethoxycarbonyl derivatives 29 [43] and 30 [42] , respectively. Next, the reaction of 29 or 30 with the corresponding halides in the presence of K 2 CO 3 as base afforded the 5-unsubti tuted derivatives of 4-methoxybenzyloxy 31, 1-naphthylmethoxy 32, 2-naphthylmethoxy 33, or the 5-nitroindazole ethers 34e36, respectively. All reactions were carried out under reflux of butanone, except for derivatives 31 and 35, where 1,4-dioxane and DMF were, respectively, the solvents of choice. In some cases, migration of the arylmethyl substituent from the O-at C3 to N2 was observed, leading to mixtures of 3-arylmethyloxy-1H-indazole and N2-alkylated 1,2-dihydro-3H-indazol-3-one derivatives (Scheme 2). For example, the reaction of derivatives 29 and 30 with the corresponding halides yielded a mixture of the corresponding indazole ethers 31e36 and their corresponding N-2 substituted derivatives 37, 38, 39 [44] , 40, 41, and 42 [45] , respectively. The relative ratio of the two isomers depended on the conditions employed in each case. To the best of our knowledge, there is no reported procedure allowing the selective O-alkylation to afford the ether isomer in good yield. Nevertheless, by tuning the reaction conditions we found conditions to obtain the desired indazole ethers 31e36 as the major component of the mixture in all cases, which could be efficiently separated from the mixture by flash chromatography (see Experimental section for detailed conditions).
For the majority of the derivatives, the best results were obtained using 2-butanone as solvent. However, for the preparation of derivative 31 the use of 1,4-dioxane was found to be essential for increasing the ratio of the desired indazole ether over that of the N2-alkylated product. As another exception to this general trend, the synthesis of derivative 35 required harsher reaction conditions and a higher boiling point solvent (DMF). The best O3-versus N2-alkylation ratio was achieved for compounds 32 and 35 for which a relative ratio of 10:1 and 5:1, respectively, was measured by 1 H NMR from the crude mixture.
With the 1H-indazole 31e36 in hand, the last step to obtain the target compounds was the installation of the aminoethyl group at N1 position. The synthesis of 4-methoxybenzyl derivative 3 and 4-methoxybenzyl-5-nitroindazoles 13, 14 were carried out with diisoproylaminoethyl chloride and pentyl iodide, from 31 and 34, respectively.
The reaction of the 1-naphthylmethoxy indazole 32 with the corresponding aminoethyl chlorides afforded the diisopropylaminoethyl, pyrrolidinyl ethyl and piperidinoethyl derivatives 5e7, respectively. In a similar manner, N-alkylation of the 5-nitro-1-naphthylmethoxy indazole 35 with 2-pyrrolydinnoethyl chloride afforded the corresponding ether 15. Finally, the preparation of the 3-(2-naphthylmethoxy)indazole derivative was carried out from 33 by N-alkylation with 2-piperidinoethyl chloride to afford the desired derivative 9.
Similarly, the reaction of the 5-nitro-2-naphthylmethoxy indazole 36 with the corresponding aminoethyl chlorides and alkyl iodides afforded the pentyl, piperidinoethyl and morpholinoethyl ethers 17e19, respectively.
Besides, we have performed novel modifications in the indazole ether system by bromination and reduction reactions (Scheme 3). In this sense, the conversion of the nitro group at C-5 into the corresponding 5-amino derivative had not been reported before. Thus, to the preparation of the 5-amino derivatives 22e24 a modification of the standard ferric chloride-promoted procedure was necessary. Following the method describes by Lauwiner et al. [46] for the reduction of monosubstituted nitrobenzenes, the ferric oxyhydroxide FeO(OH) was prepared and used as catalyst by the treatment of FeCl 3 with a NaOH solution.
Following this procedure the reaction of the 5-nitro derivatives 12, 15 and 18 with hydrazine in MeOH in presence of the ferric oxyhydroxide FeO(OH) as catalyst afforded the corresponding 5-amino derivatives 22e24, respectively. The preparation of 5-bromo indazole 25 was achieved by bromination with N-bromosuccinimide and ferric chloride from the 2-naphthylmethoxy-1-piperidinoethylindazole 9.
The structures of synthesized compounds (1e25) were established as N1 and O3 disubstituted indazoles on the basis of NMR data (Tables S1 and S2 ). The position of the 1 and 3 substituents can be distinguished by 13 C NMR spectra examining the chemical shifts (Table S2) . Thus, the signals corresponding to aromatic methylene group attach at O-3 (66e75 ppm) appears at lower field in relation to methylene N-1 (50e58 ppm). In compounds bearing the methylene groups at N-2 the signals appearing at highest field (45e47.5 ppm).
Biological assays

In vitro binding studies in cannabinoids receptors
Radioligand displacement assays were used to evaluate the affinity of the new compounds 1e25 using membranes from cells (HEK293EBNA) transfected with the CB1 or the CB2 receptors and All synthesized compounds together with their binding affinity for the cannabinoid receptor CB1 and CB2 are gathered in Table 1 . Examination of these data indicates that the evaluated derivatives bind to the receptor CB2 in mM range, except the disubstituted naphthyl derivatives 8 and 21. The comparison of the IC 50 values for inhibition of CB2R rather flat structureeactivity relationships, with values ranging from 0.24 to >10 mM. The situation is less pronounced for CB1 receptor, therefore some of the derivatives such as the diisopropylaminoethyl derivatives 3, 5, and 14 do not exhibit affinity to 40 mM. Regarding CB2 selectivity, it is interesting to mark several compounds as the nitro compounds 11, 16, 20, and especially the 5H-indazole 7 and the amino derivative 24 due to interesting pharmacological profiles that they will be discussed later.
AChE/BuChE inhibitory activity
The derivatives 1e25 were subjected to Ellman's test [47] in order to evaluate their potency to inhibit the AChE from human and BuChE from horse serum and human using donepezil as reference standard. The displayed IC 50 values in Table 2 showing that several compounds exhibit inhibitory activity of AChE or BuChE at potency levels in the submicromolar to micromolar range. Similarly to the case of cannabinoid binding assays, the quantitative value of IC 50 for several derivatives was not possible to be determined for solubility reasons Albeit, significant inhibition of AChE, with IC 50 values in the range of 10 mM, was observed for 5 and 7.
Regarding AChE inhibition, the results indicate that several indazole derivatives showed significant activity as inhibitors of this enzyme being derivatives 1 and 2 which have lower IC 50 values among the 5H-indazoles.
In relation to BuChE inhibition, several indazole derivatives showing a significative IC 50 value. The analysis of the IC 50 values reveals it is necessary but not sufficient, the presence at N1 position of a dialkylaminoethyl group like demonstrated with the 5H-indazole derivatives 3, 5, 6, 7, 9 and with the 5-amino 23, 24 and 5-bromo 25 compounds. It is interesting to mention that all the other 5H-unsubstituted indazole derivatives bearing the aminoethyl group behaved as BuChE inhibitors showing a marked selectivity towards BuChE. In the case of 5-nitroindazole derivatives only the piperidinoethyl 18 and pyrrolidinyl ethyl 15 showed inhibition of BuChE. Noteworthy, these achieved values of inhibitory activity for BuChE are comparable to those published from rivastigmine, a cholinesterase inhibitor used in Alzheimer's disease. The IC 50 of rivastigmine as AChE or BuChE inhibitor is 1.5e48 mM or 0.3e54 mM respectively, depending on the assay conditions [48e50].
Kinetic study of BuChE/AChE inhibition
To gain further insight into the mechanism of action of this family of compounds, a kinetic study was carried out with the most promising inhibitors of BuChE. LineweavereBurk plots were done for the multitarget cannabinoids and donepezil as reference compound and are shown in material supplementary (Figs. S1 and S2) and the data summarized in Table 2 . The inhibition constants, K i , for BuChE inhibitors (Table 2) were determined by fitting the kinetic data to a competitive, noncompetitive, or mixed inhibition model by nonlinear regression analysis using GraphPad Prism 5 [51] . Thus, the competition studies were carried out in all the indazole derivatives with activity as BuChE inhibitors. Albeit deserve special attention those derivatives that behave as cannabinoid agonists and BuChE inhibitors like 3, 6, 7, 9, 23 and 24 (Table 2) . Reciprocal plot for donepezil inhibition showed both increasing slopes (decreased at increasing inhibitor concentrations) and increasing intercepts with higher inhibitor concentration (Fig. S1 ). These results indicate a mixed-type inhibition and are in agreement with patterns obtained with the same enzyme [52] . Therefore, kinetic studies suggested two potential different site of interaction: the active site and the peripheral binding site.
Regarding the inhibition type of BuChE, compounds 18 and 24 ( Fig. S2) showed similar plots to donepezil pointing to a mixed type competitive BuChE inhibition mode of action. Lineweavere Burk plots obtained for 5, 6, 7, 15, 23 and 25 ( Fig. S2 ) increase in the slope at increasing inhibitor concentrations, typical for a pure competitive BuChE inhibitor. Reciprocal plot for 3 and 9 ( Fig. S2) showed unvaried y-intercepts and increasing slopes at increasing inhibitor concentrations compatible with non-competitive BuChE inhibitors.
Moreover, complementary competition studies in AChE were performed with the indazole derivatives inhibitors of BuChE that showed an IC 50 about 10 mM as AChE inhibitors like 5 and 7. In a similar way to BuChE, the analysis of the graphic profiles of 5 and 7 ( Fig. S3 ) can be established that 5 and 7 showed a competitive mode of action as AChE inhibitors.
Cannabinoid activity. Isolated tissue assays
According to the objectives, all derivatives that showed simultaneously activity as cannabinoid ligands and as inhibitors of BuChE have been studied in detail in isolated tissues. The functional activity of the new compounds 3, 5e7, 9, 15, 18 and 23e25 has been tested on mouse vas deferens (MVD) a tissue commonly used to study and characterize cannabinoid effects [53, 54] . In MVD cannabinoid agonists, acting at prejunctional cannabinoid receptors, reduce ATP and noradrenaline release and inhibit the electrically evoked smooth muscle contractions. In this tissue, cannabinoid receptor antagonists oppose the inhibitory effect of agonists in a competitive and surmountable manner. CB1 and CB2-like cannabinoid receptors seem to be involved in this effect [55, 56] .
From the tested compounds, at the used concentrations (10 À7 e 2 Â 10 À5 M), some derivatives were able to significantly modify the electrically induced contractile response. As Fig. 3 shows, compounds 3, 6, 7, 9, 15 and 23e24 induced a concentration-dependent inhibition of the electrically evoked contractions; from these data, it could be established that these compounds behave as agonists. Furthermore, the effectiveness (maximum effect) of 6, 7, 9 and 23e 24 was similar to that of the reference cannabinoid agonist WIN 55,212-2.
Considering that compounds 3, 6, 7, 9, 15, 23 and 24 showed an interesting profile as potential cannabinoid agonists, the blockade of their effect by the CB1 and CB2 receptors antagonists were tested, alone (AM251) or in combination (AM251 þ AM630). These drugs were added to the organ bath before each concentration of the new compounds (10 Results showed a partial blockade of the effect of the new derivatives 3, 9 and 24 that was maximum at the concentration of 2.7 Â 10 À6 M (Fig. 4A ), indicating that their mechanism of action includes the activation of the cannabinoid receptors CB1/CB2 confirming our hypothesis. The lack of antagonist efficacy on the inhibition induced by the highest concentration of the new compounds (2 Â 10 À5 M) suggests a surmountable antagonism, perhaps competitive (Fig. 4B) .
Compounds 3, 9 and 24 had the better profile as cannabinoid agonists because they inhibited in a concentration-dependent manner the electrically evoked contractions on mouse vas deferens and this effect was significantly blocked by CB1 and CB2 receptor antagonists.
The inhibitory effects of the MVD contraction of compounds 6, 7 and 23 are not modified by the presence in the organ bath of the cannabinoid antagonists, so they can be due to other mechanisms that not involve cannabinoid receptors and that are not the object of study in this experimental work.
Taking in consideration our present aim, compounds 5, 15, 18 and 25 did not show an interesting profile because their inhibitory effect is too slight.
Antioxidant activity
The antioxidant activities of indazole ether derivatives 3, 6, 7, 9, 23 and 24 were evaluated by following the well-established ORAC-FL method (oxygen radical absorbance capacity by fluorescence) [57, 58] . The results shown in Table 2 indicate that indazole ether derivatives exhibit antioxidant properties with values higher than 45% in relation to Trolox. The 5-aminoindazole derivatives 23 and 24 protect much more efficiently against free radicals (about to thirty percent) than the corresponding 5H-indazoles 6 and 9, respectively.
In summary, the obtained results about indazole ethers derivatives that possess simultaneously activity as cannabinoid agonists and as inhibitors of BuChE showed certain antioxidant capacity, in particular for the noncompetitive 3 and competitive inhibitor of BuChE 23. This last compound showed the most antioxidant capacity about 29% higher than Trolox.
Computational studies
To rationalize the achieved biological properties for all derivatives that showed simultaneously activity as cannabinoid agonists and as inhibitors of BuChE docking studies have been carried out employing both targets, CB2R and BuChE. These simulations were attained employing FlexiDock module of the SYBYL 7.2 suite of programs [59] .
CB2R-ligands complexes
In our group we have been working on modelling the cannabinoid receptors for several years [40, 60] . The first models in the inactive form were built with the pattern of bovine rhodopsin (pdb code: 1f88 [61] ). Later, we have modelled CB2 receptor in the active form (results not published). The docking and scoring runs were performed using FlexiDock program [59] . Fig. S4 allows us to verify that our indazole derivatives occupy a similar area that the known agonist JWH-015, showing similar interactions with the residues of the binding site [62] (see Supplementary material, Table S3 ). The results of the docking experiments for the compounds 3, 5e7, 9, 15, 18 and 23e25 in CB2R* model in terms of key interactions are gathered in Table S3 . The most important difference is the displacement of the naphthyl group due to the replacement of carbonyl group by the ether function. Probably, this displacement is translated in a weak aromatic interaction with Phe197 and Trp258. Observing the Fig. S4 , this displacement is a bit more noticeable in the 2-naphthyl derivatives. Further discussion of the docking studies with CB2R model is found in Supplementary material. 
BuChE-ligands complexes
Regarding the recognition partners between the ChEs and the cannabinoid ligands, docking simulations were done in the 3D structure of human AChE and BuChE (PDB codes: 1B41 [63] and 1P0I [64] , respectively). The interaction modes of active ChE inhibitors in AChE or BuChE were studied employing FlexiDock program [59] (see Experimental section for details). The binding gorge of AChE, which is composed of the central catalytic pocket (CAS) and the peripheral site (PAS), was taken as the binding site for docking studies. For each inhibitor, conformation with the lowest interaction energy was taken out for further analysis. In a previous work we studied an example of each known binding mode: donepezil (mixed), propidium (no-competitive) and edrophonium (competitive) in order to test our docking protocol with good results [37] . Using the same methodology, BuChE inhibitors 3, 5e7, 9, 15, 18 and 23e25 were studied and the k d values were calculated with STC program [65] ( Table 2 The best docking solutions of the most interesting compounds 3, 6, 7, 9, 15, 23 and 24 clearly show that these derivatives are located along the tunnel between the sites of the PAS and CAS BuChE (Fig. 5 , Table S4 ). Visually, it is observed that indazole derivatives orientate the group indazole of the position in N1 towards the interior of the channel, so that the indazole group is closed to Trp82. Another interesting observation is regarding to the existence of two clusters of inhibitors due to the different group in R 3 and therefore different orientation of the group, driven the kinetic of the inhibition. Thus, one of the cluster, it is formed by compounds 7, 6, and 23 (1-naphthyl substituent on R 3 ) behaving as competitive inhibitors and the second cluster, it is formed by compound 3 (1-methoxyphenyl on R 3 ) and 9 and 24 (2-naphthyl substituent on R 3 ) behaving as non-competitive.
The group at R 3 could be driving the type of inhibition since the 1-naphthyl derivatives behave as competitive inhibitors meanwhile the 2-naphthyl derivatives as non-competitive-mixed inhibitors (Fig. 6 ). This fact could be due to a relocation of the 2-naphthyl group to avoid a steric hindrance of the 2-napthyl ring with Thr284 and Pro285. Thanks to this movement of the ring, two other interactions appear, one of them with Thr120 (by hydrogen bond with the indazole nitrogen) and the other one with Ser287 (p-HB with 2-naphthyl) (Fig. S6 ) and unlocking the entrance of the triad catalytic. Further discussion of the interactions of the most representative compounds is displayed in the Supplementary material.
Conclusions
On the basis of this investigation, a novel and plausible approach based on the discovery of CB2 cannabinoid agonists that behave as BuChE inhibitors is proposed. Docking techniques have been effectively used to design new cannabinoids derivatives with an innovative indazole ether structure. Remarkably, more than 90% of evaluated compounds have shown capacity to bind CB2 cannabinoid receptor. Among them, according to tissue studies, compounds 3, 6, 7, 9, 23 and 24 behave as agonists showing a maximum effect similar to the reference cannabinoid agonist WIN 55,212-2. The AChE and BuChE inhibition studies show that these The kinetic and modelling studies have provided insights into the mode of action and the binding site of these compounds. The full agonists 3 and 9 showed a non-competitive inhibition mode, while 24 showed a mixed type inhibition mode of action. Moreover, the
In summary, the cannabinoid effect, the inhibition of the BuChE of compounds 3 (noncompetitive inhibition type) and 24 (mixed inhibition type) along with its antioxidant capacity suggest that these compounds can be regarded as a potential agent useful for Alzheimer's disease.
Experimental section
Chemistry
General
Melting points were determined with a Reichert-Jung Thermovar micro melting point apparatus and are uncorrected. The corresponding halide was added to a suspension of the 1H-3-indazolol derivative in acetone and Cs 2 CO 3. The reaction mixture was refluxed, filtered and evaporated to dryness. The residue was purified by silica gel column chromatography using a mixture of dichloromethane:hexane (1:1, 5:1) as eluent.
4.1.3. General procedure for the synthesis of indazole ethers 1-substituted 3, 5e7, 9, 13e15, 17e19 from 1H-indazole ethers.
Method B
A suspension of the 1H-3-indazolol derivative in butanone and K 2 CO 3 was treated with the corresponding halide. The reaction mixture was refluxed, filtered and evaporated to dryness. The residue was recrystallized or purified by silica gel column chromatography using the appropriate eluent.
General
To a suspension of the corresponding 5-nitroindazole 1H-3-indazolol derivative in methanol and the modified catalyst FeO(OH) under argon atmosphere, monohydrated hydrazine in excess was added. The reaction mixture was achieved at 50e70 C for 24e30 h. Then, the suspension was filtered with Zelite and the solvent evaporated to dryness. The residue was treated with water and chloroform and the organic layers evaporated to dryness yielding the corresponding indazole as red oil.
4.1.6. General procedure for the synthesis of indazoles 31e42 from 1-ethoxycarbonyl derivatives. Method E
The corresponding halide was added to a suspension of the 1-ethoxycarbonyl-3-indazolol derivative in acetone, K 2 CO 3 and catalytic amount of KI. The reaction mixture was refluxed until the end of reaction. The reaction mixture was evaporated to dryness and the residue was treated with water and chloroform. The organic layers were evaporated to dryness and a solution of 0.4 M KOH and ethanol were added. The solution was stirred at room temperature for 1 h and them evaporated to dryness and the residue was purified by silica gel column chromatography using as eluent a mixture chloroform/methanol (100:0, 80:1, 50:1). 
3-(Cyclohexylmethoxy
3-(1-Naphthylmethoxy)-1-(2-(pyrrolidin-1-yl)ethyl) indazole (6)
Following the procedure B, from 32 (0.20 g, 0.74 mmol), 2-pyrrolydinoethyl chloride hydrochloride (0.14 g, 0.79 mmol) and K 2 CO 3 (3.90 g, 2.82 mmol) in 2-butanone (60 mL). The final product was purified by chromatography column using as eluent dichloromethane:methanol (1:0, 30:1). 
3-(2-Naphthylmethoxy)-1-(2-piperidinoethyl)indazole (9)
Following the procedure B, from 33 (0.30 g, 1.10 mmol), 2-piperidinoethyl chloride hydrochloride (0.20 g, 1.10 mmol) and K 2 CO 3 (0.62 g, 4.49 mmol) in 2-butanone (60 mL). The final product was purified by chromatography column using as eluent dichloromethane:methanol (1:0, 30:1). 
1-Benzyl-3-cyclohexylmethoxy-5-nitroindazole (11)
Following the procedure C 28 (0.10 g, 0.38 mmol), cyclohexylmethyl bromide (0.10 mL, 0.70 mmol) and K 2 CO 3 (0.14 g, 0.98 mmol) in 2-butanone (60 mL). The product was purified by silica gel column chromatography using as eluent a mixture dichloromethane:hexane (1:1, 5:1). Reaction time: 24 h. Yield: (0.078 g, 60%). Mp 72e75 C (2-propanol). 1 
1-(2-Diisopropylaminoethyl)-3-(4-methoxybenzyloxy)-5-nitroindazole (14)
Following the procedure B, from 34 (0.100 g, 0.33 mmol), 2-diisopropylaminoethyl chloride hydrochloride (0.07 g, 0.33 mmol) and K 2 CO 3 (0.12 g, 0.90 mmol) in 2-butanone (60 mL). The solvent was evaporated under reduced pressure. Then, the solid is suspended in water and extracted with diethylic ether. After evaporate the ether fraction, the solid obtained is recrystallized from 2-propanol. Reaction time: 6 h. Yield: (0.12 g, 82%). Mp 83e85 C. 1 
1-(2-Morpholinoethyl)-3-(2-naphthylmethoxy)-5-nitroindazole (19)
Following the procedure B, from 36 (0.09 g, 0.28 mmol), 2-morpholinoethyl chloride hydrochloride (0.07 g, 0.40 mmol) and K 2 CO 3 (0.15 g, 0.81 mmol) in 2-butanone (60 mL). The solvent was evaporated under reduced pressure. Then, the solid is suspended in water and extracted with chloroform. After evaporate the organic phase, the solid obtained is recrystallized from 2-propanol. Reaction time: 98 h. Yield: (0.11 g, 94%) . Mp 104e106 C (2-propanol). 6 Ci/mmol) for CB2, in the presence or absence of several concentrations of the competing drug, in a final volume of 0.2 mL for CB1 and 0.6 mL for CB2 of assay buffer (50 mM TriseHCl, 2.5 mM EDTA, 5 mM MgCl 2 , 0.5 mg/mL BSA fatty acid free, pH 7.4).
Nonspecific binding was determined in the presence of 10 mM WIN 55,212-2. Silanized tubes were used throughout the experiment to minimize receptor binding loss due to tube adsorption. The reaction was terminated by rapid vacuum filtration with a filter mate Harvester apparatus (PerkineElmer) through Filtermat A GF/C filters presoaked in 0.05% polyethylenimine (PEI).
The filters were washed nine times with ice-cold buffer for CB1 (50 mM TriseHCl, 2.5 mM EDTA, 5 mM MgCl 2 , 0.5 mg/mL BSA fatty acid free, pH 7.4) for CB1 and CB2 (50 mM 
In vitro cholinesterase inhibition assays
AChE from human erythrocytes (min. 500 units/mg protein in buffered aqueous solution), BuChE from equine serum (10 units/mg protein, lyophilized powder), and BuChE from human serum (3 units/mg protein, lyophilized powder) were purchased from Sigma. Compounds were evaluated in 100 mM phosphate buffer pH 8.0 at 30 C, using acetylthiocholine and butyrylthiocholine (0.4 mM) as substrates, respectively. In both cases, 5,5-dithio-bis(2-nitrobenzoic)acid (DTNB, Ellmans reagent, 0.2 mM) was used and the values of IC 50 were calculated by UV spectroscopy from the absorbance changes at 412 nm. Experiments were performed in triplicate.
Kinetic study of BuChE/AChE inhibition
To investigate the mechanism of action of the compounds on AChE or BuChE, a kinetic analysis was performed. The experiments were carried out using combinations of four substrate concentrations, and three inhibitor concentrations. Double-reciprocal LineweavereBurk plotting of the data obtained, in which each point is mean of three different experiments, were analyzed.
Competitive inhibitors have the same y-intercept as uninhibited enzyme (since V max is unaffected by competitive inhibitors the inverse of V max also doesn't change) but there are different slopes and x-intercepts. Non-competitive inhibition produces plots with the same x-intercept as uninhibited enzyme (K m is unaffected) but different slopes and y-intercepts. Uncompetitive inhibition causes different intercepts on both the y-and x-axes but the same slope. Mixed inhibitors causes intersect above or below the x-axes.
The K i , values were determined by fitting the kinetic data to a competitive, noncompetitive, or mixed inhibition model by nonlinear regression analysis using GraphPad Prism [51] .
Functional activity for cannabinoid receptors on isolated tissue
The functional activity of the new compounds for CB1 receptors was evaluated on the mouse vas deferens preparation. This is a nerve-smooth muscle preparation that serves as a highly sensitive and quantitative functional in vitro bioassay for cannabinoid receptor agonists. These ligands induce concentration-related decreases in the amplitude of electrically evoked contractions of the vas deferens by acting on naturally expressed prejunctional neuronal cannabinoid receptors to inhibit release of the contractile neurotransmitters, noradrenaline and ATP, that is provoked by the electrical stimulation [56] .
For this study, male ICR mice weighing 25e30 g were used. Mouse vas deferens were isolated as described by Hughes [68] . Tissues were suspended in a 10 mL organ bath containing 5 mL of Krebs solution (NaCl 118; KCl 4.75; CaCl 2 2.54; KH 2 PO 4 1.19; MgSO 4 1.2; NaHCO 3 25; glucose 11 mM) that was continuously gassed with 95% O 2 and 5% CO 2 . Tissues were kept under 0.5 g of resting tension at 37 C and were electrically stimulated through two platinum ring electrodes. They were subjected to alternate periods of stimulation (trains of five rectangular pulses of 70 V, 15 Hz and 2 ms duration each were applied every minute) and rest (10 min). The isometric force was monitored by computer using a MacLab data recording and analysis system.
The effect of the synthetic cannabinoid agonist WIN 55,212-2 and that of the new compounds 3, 5e7, 9, 12, 15, 18, 23, and 24, (10 À7 e2 Â 10 À5 M) was tested by constructing concentratione response curves in a step by step manner. Curves were carried out by the following protocol: WIN 55,212-2 or the new compounds were added at a concentration to the organ bath 50 min after the beginning of electrical stimulation and their effect on the electrically induced contractions was evaluated 10 min after their addition. Then, the electrical stimulation was stopped, Krebs solution was replaced and the following concentration of the compound was added. This protocol was repeated for every concentration of the curve.
To test the involvement of the CB1 and CB2 receptors in the effect of the most interesting compounds, they were tested in tissues incubated with the cannabinoid CB1 receptor antagonist AM251 (10 À6 M) or the combination of both CB1 and CB2 receptor antagonists, AM251 and AM630 (10 À6 M) respectively. Concentrationeresponse curves for the new compounds were constructed in a step by step manner as follows:
AM251 or the combination of both antagonists was added to the organ bath 50 min after the beginning of electrical stimulation and 10 min later, a dose of WIN 55, 212-2 or the new compounds was added and its effect on the electrically induced contractions was tested 10 min later. Then, the electrical stimulation was stopped, Krebs solution was replaced and this protocol was repeated for every dose of concentrationeresponse curve.
Results have been expressed as % of inhibition, taking the mean amplitude of the last five contractions before the first addition of the agonist as 100%. Each tissue was employed to construct only one concentrationeresponse curve.
Drugs: WIN 55,212-2, AM251 and AM630 were obtained from TOCRIS (Biogen Científica S.L., Madrid, Spain); they were dissolved in ethanol 1 mg:1 mL and subsequently in ethanol and Tween 80 (1:2) after which the ethanol was evaporated [55] and saline solution (0.9%) was added.
The new compounds were dissolved in ethanol, getting a first concentration of 10 À2 M that was further diluted in distillate water.
Oxygen radical absorbance capacity assay
The ORAC-FL method of Ou et al. [57] partially modified by Dávalos et al. [58] was followed, using a Polarstar Galaxy plate reader (BMG Labtechnologies GmbH, Offenburg, Germany) with 485-P excitation and 520-P emission filters. The equipment was controlled by Fluorostar Galaxy software (version 4.11-0) for fluorescence measurement. 2,2 0 -Azobis(amidinopropane) dihydrochloride (AAPH), (AE)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox), and fluorescein (FL) were purchased from SigmaeAldrich. The reaction was carried out in 75 mM phosphate buffer (pH 7.4), and the final reaction mixture was 200 mL. Antioxidant (20 mL) and FL (120 mL, 70 mM, final concentration) solutions were placed in a black 96-well microplate (96F untreat, Nunc). The mixture was preincubated for 15 min at 37 C, and then AAPH solution (60 mL, 12 mM, final concentration) was added rapidly using a multichannel pipette. The microplate was immediately placed in the reader and the fluorescence recorded every minute for 80 min. The microplate was automatically shaken prior each reading. Samples were measured at eight different concentrations (0.1e1 mM). A blank (FL þ AAPH in phosphate buffer) instead of the sample solution and eight calibration solutions using Trolox (1e8 mM) were also used in each assay. All the reaction mixtures were prepared in duplicate, and at least three independent assays were performed for each sample. Raw data were exported from the Fluostar Galaxy software to an Excel sheet for further calculations. Antioxidant curves (fluorescence vs time) were first normalized to the curve of the blank corresponding to the same assay, and the area under the fluorescence decay curve (AUC) was calculated. The net AUC corresponding to a sample was calculated by subtracting the AUC corresponding to the blank. Regression equations between net AUC and antioxidant concentration were calculated for all samples. ORAC-FL values were expressed as Trolox equivalents by using the standard curve calculated for each assay, where the ORAC-FL value of Trolox was taken as 1.
Docking studies
All calculations were performed using the SYBYL 8.1 program suite [Tripos Inc., St. Louis. Mo 1] . The docking studies were achieved using the FlexiDock module of the SYBYL 8.1 suite of programs.
The structures of the ligands were built with standard bond lengths and angles using the molecular modelling package SYBYL 8.1 and their energies were minimized using the conjugate gradient algorithm with a conjugated gradient of <0.001 kcal/mol convergent criteria provided by the MMFF94 force field [69, 70] and MMFF94 electrostatic charges.
The structure of AChE and BuChE (pdb code: 1B14 and 1P0I) were edited, protein hydrogen atoms were added and partial charges were calculated using AMBER procedure. Positions of the hydrogen atoms were refined with the use of AMBER force field.
The ligands were placed manually in the gorge limited by PAS and CAS in AChE and BuChE. The ligandereceptor complex was subjected to energy minimization using the MMFF94 force field and MMFF94 electrostatic charges and their energies were minimized using the protocol previously indicated with a conjugate gradient of <0.1 kcal/mol convergent criteria. A distance-dependent dielectric constant was used in all the calculations. These complexes were the input structure for docking using FlexiDock command. During the flexible docking analysis, the ligands and a sphere of 6 A around the corresponding ligand were considered flexibles. For each complex three flexible docking analysis were run. The default FlexiDock parameters were utilized in all cases, with maximum and minimum iterations (MI) set for each complex according to MI ¼ [No. of rotatable bonds in the protein þ No. of rotatable bonds in the ligand þ 6 Â 1000 À 500, obtaining a series of model complexes.
The conformations were analyzed in terms of interactions between ligand and the known key residues. We choose the conformation with highest FlexiDock score (better interactions) and refine the minimization energy step using a conjugate gradient of <0.01 kcal/mol convergent criteria. Analysis of the refined receptoreligand complex models was based on hydrogen bond, aromatic and hydrophobic interactions predicted with the LPC program [71] and the values of DG binding and dissociation constants obtained from the difference accessible surface area method using the STC program [65] .
